戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  injected dose (range, 0.64-12.41 percentage injected dose).
2 rter imaging times or, equivalently, a lower injected dose.
3  organ region-of-interest data normalized by injected dose.
4  h after injection, with uptake of 1% of the injected dose.
5 rate density (NECRD) curves as a function of injected dose.
6 e was a median 102% (range, 78%-113%) of the injected dose.
7 rsed when corrected as a percentage of total injected dose (0.022% versus 0.017%, P = .003).
8  of brain tissue +/- 0.30 or 0.00019% of the injected dose 1 week after dosing.
9  of brain tissue +/- 0.10 or 0.00011% of the injected dose) 20 weeks after dosing.
10 basis of the data for these 4 patients (mean injected dose, 231 MBq), the radiation exposure of a (68
11 rily renal clearance (mean 25.7% +/- 5.4% of injected dose 4 h after injection).
12 ddition to blood activity and PET/CT system, injected dose affected quantification of arterial 18F-Na
13  tracer uptake in the pancreas normalized by injected dose and body weight.
14 ctivity for calculation of SLN percentage of injected dose and extraction.
15 wed high renal excretion (83.2% +/- 7.3%) of injected dose and rapid blood clearance.
16 n steps, corrected for radiotracer decay and injected dose, and fitted to a bicompartmental model.
17 d lesion detectability, reduced scan time or injected dose, and more accurate and precise lesion upta
18                   Therefore, blood activity, injected dose, and PET/CT system should be considered to
19 8F-NaF uptake is affected by blood activity, injected dose, and PET/CT system.
20 comparable in the total duration of seizure, injected dose, and time from the injection to the image
21  uptake, distinct image contrast despite low injected doses, and rapid clearance from blood.
22  a t(1/2) of 24 h and accumulated to 1.7% of injected dose at 24 h following i.v. delivery.
23          Uptake of CMICE-013 was 1.5% of the injected dose at rest and increased more rapidly with in
24  their ideal renal clearance efficiency (60% injected doses at 24 h postinjection), the reporters can
25 apable of increasing the efficacy of a given injected dose by improving both pharmacokinetic profile
26 ated whether blood activity, renal function, injected dose, circulating time, and PET/CT system affec
27 h a standard rat brain atlas, and percentage injected dose/cm(3) and binding potential (simplified re
28 nfirmed by radiochromatography and was 0.05% injected dose/cm(3) as measured by PET/CT.
29 al hemisphere, with 9.16 +/- 2.13 percentage injected dose/cm(3) at the end of infusion.
30 ateral hemisphere (23.58 +/- 4.46 percentage injected dose/cm(3)) and negligible uptake in the contra
31 Results: (11)C-methionine uptake (percentage injected dose/cm(3)) peaked in the MI region on day 3 (5
32 olabeled 28H1 in inflamed joints (percentage injected dose) correlated with the arthritis score (Spea
33 to define a clinically useful lower limit of injected dose for (68)Ga-prostate-specific membrane anti
34 he 14-min acquisition or 125.8-MBq (3.4-mCi) injected dose for the 10-min acquisition.
35 vel would correspond to a 92.5-MBq (2.5-mCi) injected dose for the 14-min acquisition or 125.8-MBq (3
36  systems provide an opportunity to lower the injected doses for SPECT myocardial perfusion imaging (M
37 ulation of (99m)Tc-SPIONs (as the percentage injected dose/g [%ID/g]) in the SLN was 100 %ID/g, where
38 .1% injected dose/g after 24 h; 81% +/- 7.5% injected dose/g after 1 wk) after intraperitoneal admini
39 ated predominantly in tumors (32.8% +/- 8.1% injected dose/g after 24 h; 81% +/- 7.5% injected dose/g
40 e for *I-SGMIB-Nanobody was 24.50% +/- 9.89% injected dose/g at 2 h, 2- to 4-fold higher than observe
41 take in thyroid, salivary glands (percentage injected dose/g at 30 min, 563 +/- 140 and 32 +/- 9, res
42 /- 9, respectively), and stomach (percentage injected dose/g at 90 min, 68 +/- 21).
43 images, with 2.9% +/- 0.3% and 3.7% +/- 0.2% injected dose/g for the pexidartinib- and vehicle-treate
44 showed a specific uptake of approximately 4% injected dose/g of tumor (reduced to ~0.3% with a 50-fol
45  (3.56 +/- 0.81 and 1.30 +/- 0.18 percentage injected dose/g without and with pretreatment, respectiv
46 8% radiochemical yield and showed high (>10% injected dose/g) and sustained accumulation in LNCaP tum
47 st melanoma uptake (22.3 +/- 1.72 percentage injected dose/g) at 2 h after injection.
48 take to a level (approximately 10 percentage injected dose/g) comparable to that obtained with radiom
49 owed tumor uptake after 3 d (19.7% +/- 17.0% injected dose/g) comparable to that of (111)In-DTPA-MN-1
50                  The high tumor uptake (~56% injected dose/g) warrants clinical investigation of [(89
51 77)Lu-tetrazine tumor uptake (6.9 percentage injected dose/g) was observed with low renal retention,
52          High tumor uptake (10.11% +/- 1.67% injected dose/g, n = 5) was detected at 60 min after inj
53 ol mice (5.17% +/- 1.18% vs. 2.41% +/- 0.34% injected dose/g, P = 0.02), as corroborated by imaging.
54  2.59%, 8.36% +/- 2.15%, and 3.09% +/- 0.58% injected dose/g, respectively).
55 on, reaching 9.1% +/- 0.5% and 7.6% +/- 1.2% injected dose/g, respectively, at 60 min after injection
56 fforded a tumor uptake of approximately 10 % injected dose/gram, owing to a long circulation half-lif
57 the mean (111)In-panitumumab uptake of 29.6% injected dose (ID) per gram +/- 2.2 (standard error of t
58             The highest concentration of the injected dose (ID) was found in the fetal kidney (0.0161
59 10 mug of (89)Zr-RO5323441 was 8.2% +/- 1.7% injected dose (ID)/cm(3) at 144 h after injection, and i
60  ultrahigh accumulation of approximately 30% injected dose (ID)/g in 4T1 murine breast tumors in Balb
61 al PET (postoperative day 4), and percentage injected dose (%ID) as a parameter of T-cell infiltratio
62  an 87% +/- 3% decrease in the percentage of injected dose (%ID) in all identified disease sites.
63 ntral skeleton varied between 11% and 56% of injected dose (%ID) or between 1.8 and 10.5 %ID/1,000 mL
64                  SPECT-quantified percentage injected dose (%ID) was calculated and compared with the
65 eft ventricular [LV] volume), and percentage injected dose (%ID) were calculated, and visual grading
66  in the tumor, with 30.8 +/- 12.6 percentage injected dose (%ID)/g at 1 h after injection.
67 in the saline control group (mean = 4.43% of injected dose [ID] per gram of tissue vs 0.99% of inject
68 take in the 231 G521R ER xenografts (percent injected dose [ID] per gram, 0.49 +/- 0.042), which was
69  tissue gadolinium levels at 24 hours (<3.9% injected dose [ID]/g +/- 0.6) and 10-fold lower levels a
70 acer exhibited good tumor localization (3.4% injected dose [ID]/g +/- 1.0 [standard deviation] at 1 h
71  By 72 h, tumor and liver uptake (percentage injected dose [%ID]) reached 15.37 +/- 5.21 %ID g(-1) an
72         The highest tumor uptake (percentage injected dose [%ID]) was observed at 2 h after injection
73 on (70.3 +/- 1.3 and 73.8 +/- 3.0 percentage injected dose [%ID], respectively, at 90 min after injec
74 h after injection (18.13 +/- 1.73 percentage injected dose [%ID]/g and 11.81 +/- 2.05 %ID/g, respecti
75 ghest tumor uptake (23.1 +/- 6.11 percentage injected dose [%ID]/g at 1 h after injection).
76 rs (2.4 +/- 0.17 vs. 1.6 +/- 0.14 percentage injected dose [%ID]/g at 2 h after injection, P = 0.006)
77  sham mice on day 3 (10.5 +/- 4.1 percentage injected dose [%ID]/g vs. 3.8 +/- 0.9 %ID/g, P < 0.001)
78 231 tumor xenografts (5.7 +/- 0.9 percentage injected dose [%ID]/g) at 3 h after intravenous administ
79  high peak uptake (836.6 +/- 86.6 percentage injected dose [%ID]/g) compared with background liver (2
80 higher for (18)F-FET (3.5 +/- 0.8 percentage injected dose [%ID]/g) than for (64)Cu-NOTA-AE105 (1.2 +
81 in isothiocyanate (10.86 +/- 0.94 percentage injected dose [%ID]/g), IRDye800CW (13.66 +/- 3.73 %ID/g
82  min after injection (9.2 +/- 2.0 percentage injected dose [%ID]/g).
83 her for (18)F-hGTS13 (7.5 +/- 0.9 percentage injected dose [%ID]/g, n = 3) than for (18)F-FSPG (4.6 +
84 : 5.44 +/- 0.37 vs. 3.33 +/- 0.20 percentage injected dose [%ID]/g, P < 0.05).
85                                   Percentage injected doses (%IDs) corrected for radioactive decay in
86 F-NaF uptake based on the ratio of (18)F-NaF injected dose in (18)F(-)/(18)F-FDG PET/CT.
87 distribution and rapid renal excretion (>80% injected dose in 4 h), compared to native deferoxamine (
88 ein binding, red cell uptake, and percentage injected dose in the urine at 30 and 180 min were determ
89  no significant difference in the percentage injected dose in the urine at 30 min (P = 0.24) and at 3
90               In normal rats, the percentage injected dose in urine at 10 and 60 min for both prepara
91    Based on histological evaluations, at the injected doses investigated, the particles did not show
92 ulsion (AUClast in plasma - 20.2+/-1.86min*%/injected dose/ml) and solution form (AUClast in plasma -
93 tem (AUClast in plasma - 263.89+/-21.81min*%/injected dose/ml) as compared to the cationic nanoemulsi
94 n form (AUClast in plasma - 44.9+/-1.24min*%/injected dose/ml) respectively.
95 tial concentration in blood was 22.4% of the injected dose/mL, and annexin A5-CCPM was mainly distrib
96 r vessels was achieved using a ~6-fold lower injected dose of (12,1) and (11,3) SWNTs (~3 mug per mou
97 were enrolled and received a single 3 MBq/kg injected dose of (18)F-FDG followed by a dual-imaging PE
98       After 10 minutes, 4.5% +/- 1.1% of the injected dose of (213)Bi was delivered per gram of tumor
99 umor-absorbed dose of 43.8 Gy per millicurie injected dose of (90)Y, with tumor-to-normal organ dose
100                              A 10-fold-lower injected dose of 0.555 MBq (15 muCi) of (18)F-FES was al
101                                      With an injected dose of 10 mCi (370 MBq) and a 1-hour voiding i
102 s very low (0.71 +/- 0.07 mSv for a standard injected dose of 100 MBq).
103  effective dose was 2.32 +/- 0.32 mSv for an injected dose of 20 MBq in newborns.
104 he interstitial fluorescence saturated at an injected dose of 20mg/kg.
105 -y-old children and 0.59 +/- 0.05 mSv for an injected dose of 30 MBq in 5-y-old children.
106 ly entered the monkey brain (peak percentage injected dose of approximately 6.6%), and its brain dist
107                               The percentage injected dose of CMICE-013 taken up by the heart was gre
108 rend correlated with change in percentage of injected dose of FDG in tumor for all groups (R(2) = 0.8
109  tumor volume, calculation of the percentage injected dose of fluorine 18 fluorodeoxyglucose (FDG) in
110 hip between MRI contrast enhancement and the injected dose of gadopiclenol in a glioma rat model comp
111                                              Injected doses of 200ng/mg body weight led to mortality
112  factor of 4-6 reduction in imaging time (or injected dose) over the mCT Flow when using the ALROC me
113  (0.06 +/- 0.01 vs. 0.16 +/- 0.05 percentage injected dose, P < 0.01), PET imaging (maximum SUV, 3.8
114 .02% vs. 0.25% +/- 0.04% and 0.24% +/- 0.03% injected dose, P < 0.05), with retention of all 3 tracer
115 n a GD2-negative tumor (9.8% vs. 1.3% of the injected dose per cc, respectively).
116 diastolic volume from 1 to 12 wk (percentage injected dose per centimeter cubed, 0.15 +/- 0.07 vs. 0.
117  (18)F-FLT uptake was reported in percentage injected dose per cubed centimeter by drawing regions of
118 in the pulmonary LNs (6.8 +/- 1.1 percentage injected dose per cubic centimeter [%ID/cm(3)]) 24 h aft
119 sing tumors, reaching 5.6 +/- 1.2 percentage injected dose per cubic centimeter at 40-60 min and rapi
120  (0.87 +/- 0.06 vs. 1.11 +/- 0.09 percentage injected dose per cubic centimeter in control group, P <
121 data analysis was performed using percentage injected dose per cubic centimeter of tissue (%ID/cm(3))
122 average concentration, 30.1% +/- 4.6% of the injected dose per cubic centimeter).
123 I rats or sham-operated controls (percentage injected dose per cubic centimeter, 0.20 +/- 0.05 vs. 0.
124 eduction in aortic tracer uptake (percentage injected dose per cubic centimeter, 0.95 +/- 0.04 vs. 1.
125 the non-targeted w-MWNT in vivo reaching ~2% injected dose per g of brain (%ID/g) within the first ho
126 A-UBI29-41 peaked at 3.8 +/- 0.91 percentage injected dose per gram (%ID) at 120 min, and 88 +/- 5.2
127 with a mean uptake of 2.5 +/- 0.3 percentage injected dose per gram (%ID/g) (mean +/- SEM) 4 h after
128 her tissue, peaking at 100 +/- 21 percentage injected dose per gram (%ID/g) 24 h after injection, a v
129 11)In had a remarkable tumor uptake of 43.2% injected dose per gram (%ID/g) 72 hours after tail vein
130 ce of approximately 1.10 +/- 0.20 percentage injected dose per gram (%ID/g) and 0.90 +/- 0.12 %ID/g,
131 ith tumor uptake of 0.76 +/- 0.09 percentage injected dose per gram (%ID/g) at 30 min after injection
132 32.17 +/- 7.99 and 15.79 +/- 6.44 percentage injected dose per gram (%ID/g) at 5 and 24 h, respective
133 vel of 3.4 +/- 0.1 to 9.5 +/- 0.4 percentage injected dose per gram (%ID/g) at 6 h after injection on
134  ultimately reaching 22.3 +/- 6.3 percentage injected dose per gram (%ID/g) at 72 h after injection.
135 e of (111)In-28H1 ranged from 2.2 percentage injected dose per gram (%ID/g) in noninflamed joints to
136  of 12.4 +/- 2.3 and 22.7 +/- 3.3 percentage injected dose per gram (%ID/g) of tissue, respectively,
137 m 23 +/- 15, 8 +/- 4, and 2 +/- 1 percentage injected dose per gram (%ID/g) to 11 +/- 11 (P < 0.001),
138 ersus control groups (3.0 +/- 0.0 percentage injected dose per gram (%ID/g) vs. 21.0 +/- 3.4 %ID/g, r
139 Organs and tumors were dissected, percentage injected dose per gram (%ID/g) was determined, and dosim
140  tumor uptake of approximately 40 percentage injected dose per gram (%ID/g) was observed at 3-4 d aft
141 ion, tumor uptake was 4.4 +/- 0.8 percentage injected dose per gram (%ID/g), 5.6 +/- 1.6 %ID/g, and 7
142 bited 2.3 +/- 0.6 and 1.3 +/- 0.4 percentage injected dose per gram (%ID/g), respectively, in BxPC3 x
143 d from 5.3 and 3.5 to 3.0 and 2.4 percentage injected dose per gram (%ID/g), respectively.
144 9, 22.1 +/- 1.9, and 22.7 +/- 1.7 percentage injected dose per gram (%ID/g), respectively.
145 r injection, tumor uptake was 4.4 percentage injected dose per gram (%ID/g), significantly greater th
146 hanced tumor uptake [42.9 +/- 9.5 percentage injected dose per gram (%ID/g); n = 4] and tumor-to-back
147 ts exhibited tumor uptake of 0.58% +/- 0.06% injected dose per gram (ID/g) for [(125)I]11a and 1.12%
148 ecific tumor uptake of 11 and 2.3 percentage injected dose per gram 24 h after injection, respectivel
149 lower tumor uptake (3.62 +/- 1.18 percentage injected dose per gram [%ID/g] 22Rv1xPSCA, 3.63 +/- 0.59
150 ifference between PD-L1-positive (percentage injected dose per gram [%ID/g] = 2.56 +/- 0.33) and -neg
151 tive PC-3 xenografts in mice (4.4 percentage injected dose per gram [%ID/g] [(99m)Tc-SARNC4] to 12.0
152 ulted in high tumor uptake (17.56 percentage injected dose per gram [%ID/g] at 4 h after injection),
153 enografts (SK-RC-52, 31.5 +/- 9.6 percentage injected dose per gram [%ID/g] at 72 h after injection).
154 knockdown of hCtr1 (4.02 +/- 0.31 percentage injected dose per gram [%ID/g] in Lenti-hCtr1-shRNA-PC-3
155  for (111)In-3BP-227 (8.4 +/- 3.1 percentage injected dose per gram [%ID/g]) and at 3 h after injecti
156  in arthritic ankles (2.2 +/- 0.2 percentage injected dose per gram [%ID/g]) and forepaws (2.1 +/- 0.
157  was highest in H441 (6.2 +/- 1.1 percentage injected dose per gram [%ID/g]) and lowest in Calu-1 (2.
158  at 1 h after injection (>300-400 percentage injected dose per gram [%ID/g]) but decreased by 2-3-fol
159 hest uptake of (111)In-bsRICs (7.8% +/- 2.1% injected dose per gram [%ID/g]) in BT-474 human breast c
160 lent tracers ( approximately 0.60 percentage injected dose per gram [%ID/g]) than for trivalent trace
161 EM1 tumors at 4 h (153.2 +/- 22.2 percentage injected dose per gram [%ID/g]), 24 h (127.1 +/- 42.9 %I
162 tumors after 24 h (20.35 +/- 7.50 percentage injected dose per gram [%ID/g]), 48 h (22.82 +/- 3.58 %I
163 -positive) was high (36.8 +/- 7.8 percentage injected dose per gram [%ID/g]), whereas uptake in MKN45
164 n after injection (26.35 +/- 1.52 percentage injected dose per gram [%ID/g]).
165 0 mug/mouse or less (13.5 +/- 5.2 percentage injected dose per gram [%ID/g]).
166 l (1 h: DX3purobeta6, 2.3 +/- 0.2 percentage injected dose per gram [%ID/g]; DX3purobeta6/DX3puro rat
167 . 3.88 +/- 1.00 vs. 2.36 +/- 1.25 percentage injected dose per gram [%ID/g]; P < 0.0001).
168 mor xenografts of approximately 6 percentage injected dose per gram and good tumor retention for at l
169 f (18)F-FPPRGD2 was quantified by percentage-injected dose per gram and target-to- BACKGROUND: =0.003
170 11)In-DOTA-Z09591 was 7.2 +/- 2.4 percentage injected dose per gram and the tumor-to-blood ratio was
171 n LNCaP xenografts ranged from 9.3% to 12.4% injected dose per gram at 1 h after injection and from 7
172 red rapidly from the blood (<0.07 percentage injected dose per gram at 1 h after injection), mainly v
173 0.3, 3.4 +/- 0.3, and 2.4 +/- 0.3 percentage injected dose per gram at 1, 4, 15, and 36 h after injec
174 g 5.85 +/- 0.79 and 8.13 +/- 1.46 percentage injected dose per gram at 10 and 60 min, respectively.
175 significant pancreas uptake (7.37 percentage injected dose per gram at 15 min), most likely due to th
176 sitive LNCaP tumors (45.8 +/- 8.0 percentage injected dose per gram at 168 h after injection), wherea
177  significantly lower (6.6 +/- 1.3 percentage injected dose per gram at 168 h after injection).
178  19.05 +/- 5.04 and 18.6 +/- 3.56 percentage injected dose per gram at 2 and 4 h after injection, res
179 a high initial brain uptake (6.45 percentage injected dose per gram at 2 min) and rapid brain washout
180 d in the best uptake (8.2 +/- 1.7 percentage injected dose per gram at 20 h after injection) and tumo
181 ze over time, reaching around 5.0 percentage injected dose per gram at 20 h after injection.
182 -PAS200 were applied (respective percentages injected dose per gram at 24 h after injection: 12.3 and
183  +/- 24.4 at 1 h to 2.13 +/- 1.36 percentage injected dose per gram at 24 h.
184 ors (19.0 +/- 3.6 vs. 2.7 +/- 1.6 percentage injected dose per gram at 3 and 69 h after injection, re
185 AR2-MMAE, reaching 119.7 +/- 37.4 percentage injected dose per gram at 3 d after injection.
186 .6 +/- 3.9, 28.6 +/- 6.0, and >35 percentage injected dose per gram at 4 h after injection, respectiv
187 8, 10.4 +/- 0.8, and 16.5 +/- 2.6 percentage injected dose per gram at 4, 24, and 48 h after injectio
188 negative A549 tumors (4.3 +/- 0.2 percentage injected dose per gram at 48 h after injection; n = 3).
189 itive HCC4006 tumors (9.4 +/- 0.5 percentage injected dose per gram at 48 h after injection; n = 4) a
190 tion and tumor uptake reached 4.2 percentage injected dose per gram by 20 min.
191 or uptake for 1F5(scFv)SA was 16.5% +/- 7.0% injected dose per gram compared with 2.3% +/- .9% inject
192 mor-specific uptake (13.0 and 8.5 percentage injected dose per gram for (64)Cu-SarAr-SA-Aoc-bombesin(
193 ion (16.5 +/- 2.8 and 8.6 +/- 1.3 percentage injected dose per gram for apoA-I- and phospholipid-labe
194 ted dose per gram compared with 2.3% +/- .9% injected dose per gram for the control FP.
195  phenotype, reaching at least 5.0 percentage injected dose per gram in all 3 tumor models.
196 ages were analyzed by calculating percentage injected dose per gram in MR-guided ROIs.
197 HYNIC-28H1 uptake ranged from 1.5 percentage injected dose per gram in noninflamed joints to 22.6 per
198 ram in noninflamed joints to 22.6 percentage injected dose per gram in severely inflamed joints.
199 nce and uptake of approximately 8 percentage injected dose per gram in SKOV-3 tumors, with tumor-to-b
200  (1.24 +/- 0.07 vs. 0.57 +/- 0.08 percentage injected dose per gram in the unirradiated tumors; P < 0
201  characteristic curve analyses of percentage injected dose per gram measured from quantitative small-
202 n untreated atherosclerotic animals (percent injected dose per gram MPI uptake, 0.11 +/- 0.04%).
203 n accumulation, providing 33.90 +/- 9.06% of injected dose per gram of brain tissue (%ID/g) in the co
204 hing the brain was approximately 0.2% of the injected dose per gram of brain tissue (ID/g).
205 (18)F-RL-I-5F7 was 28.97 +/- 3.88 percentage injected dose per gram of tissue (%ID/g) at 1 h and 36.2
206  xenografts rose from less than 1 percentage injected dose per gram of tissue (%ID/g) to 14 %ID/g at
207 mice than in WT mice, measured as percentage injected dose per gram of tissue (P = 0.01).
208 cortex of TBI mice (1.15 +/- 0.53 percentage injected dose per gram of tissue [%ID/g]) than in the un
209 r uptake of [(18)F]FGlc-FAPI (4.5 percentage injected dose per gram of tissue [%ID/g]) than of [(68)G
210  relatively constant from 18 h (5 percentage injected dose per gram of tissue [%ID/g]) to 48 h (3 %ID
211 rrow and spleen within 24 hours (18% and 79% injected dose per gram of tissue [ID/g], respectively),
212 I and (18)F-FDG was quantified by percentage injected dose per gram of tissue and normalized to total
213 lowed by a slower decrease to 4-5 percentage injected dose per gram of tissue at 1 h.
214  rapid brain washout (ratio of percentage of injected dose per gram of tissue at 2 and 30 min after i
215        Because of its high tumor uptake (90% injected dose per gram of tissue at 2 h postinjection) a
216 e known brain distribution of sEH, with 5.2% injected dose per gram of tissue at peak uptake.
217 s of standardized uptake value or percentage injected dose per gram of tissue for absolute values; im
218 geting capability, with almost 10 percentage injected dose per gram of tissue in HER2-expressing tumo
219 ors expressing PARP-1 (3.2% +/- 0.36% of the injected dose per gram of tissue in PSN-1 xenografts), c
220                               The percentage injected dose per gram of tissue in the treated and cont
221 c fluid was 0.028 x 10(-5) %ID/g (percentage injected dose per gram of tissue) 50 days after administ
222 Bone marrow uptake and retention (percentage injected dose per gram of tissue) at 24 h was 6.98 +/- 2
223 .7 nM), and significant tumor uptake (<=5.4% injected dose per gram of tissue) in biodistribution stu
224 y (111)In-anti-gammaH2AX-TAT (defined as >5% injected dose per gram of tissue) was 96 d, compared wit
225 take was measured at 12.0 +/- 2.0 percentage injected dose per gram of tissue.
226    Tracer uptake was expressed as percentage injected dose per gram of tissue.
227  min after radiotracer injection (percentage injected dose per gram of tissue: 1.92 +/- 0.43 vs. 0.90
228 ted dose [ID] per gram of tissue vs 0.99% of injected dose per gram of tissue; P < .001).
229 ors than in A549 tumors, with percentages of injected dose per gram of tumor of 0.84 +/- 0.09 and 0.4
230 fter injection varied from 10% to 22% of the injected dose per gram of tumor tissue.
231 tumor vasculature at about 5% and 10% of the injected dose per gram organ (ID/g) for untargeted and R
232 in U87-stb-CXCR4 tumors, with the percentage injected dose per gram reaching a maximum of 102.70 +/-
233 ake was rapid, and there was 3.34 percentage injected dose per gram remaining at 60 min after injecti
234          Tumor uptake measured as percent of injected dose per gram tissue (%ID/g) at 3 hours was 4.3
235 though tumor uptake was low (0.65% +/- 0.04% injected dose per gram tissue [%ID/g]), it was still hig
236  of fluorescently labeled GPUs (~7% of total injected dose per gram tissue) in the lung tumor regions
237 positive tumor cells (mean, ~0.05 percentage injected dose per gram) and in antigen-positive normal c
238  and showed good tumor uptake (10 percentage injected dose per gram) and retention and a greater than
239 the LNCaP xenograft (4.5% +/- 1.8 percentage injected dose per gram) and the kidneys (106% +/- 23 per
240 ctive matriptase was high in xenografts (28% injected dose per gram) and was blocked in vivo by the a
241 racers, with low renal uptake (<4 percentage injected dose per gram) for (111)In-JVZ-007-cys already
242 , and the uptake of (18)F-SKI696 (percentage injected dose per gram) for each organ was calculated.
243 pecific tumor uptake (8.0 +/- 2.4 percentage injected dose per gram) in LNCaP tumor-bearing mice was
244                      Mean uptake (percentage injected dose per gram) of the dual-labeled tracer in tu
245 ptake at the target site (0.5-0.8 percentage injected dose per gram) that persisted over 5 h, produci
246  (1.69 +/- 0.25 vs. 1.50 +/- 0.33 percentage injected dose per gram), but oxaliplatin/cyclophosphamid
247  of uptake in the tumor (4.1 +/- 0.3 percent injected dose per gram), coupled with the fecal excretio
248 ptake in M21 tumor (2.42 +/- 0.21 percentage injected dose per gram), fast renal excretion, and low b
249     The uptake in the liver (<0.5 percentage injected dose per gram), kidneys, and blood were similar
250 39, 5.24 +/- 0.29, 5.30 +/- 0.98 (percentage injected dose per gram), respectively.
251 15 was in the thrombus (1.0+/-0.2 percentage injected dose per gram), with low off-target accumulatio
252 68)Ga-IMP288 uptake (27.5 +/- 5.8 percentage injected dose per gram), with ratios of 13.6 +/- 4.8, 66
253  (0.95 +/- 0.36 vs. 1.99 +/- 0.54 percentage injected dose per gram).
254  (1.20 +/- 0.31 vs. 2.84 +/- 0.93 percentage injected dose per gram).
255 ormal colonic mucosa (mean, ~0.03 percentage injected dose per gram).
256 ram) and the kidneys (106% +/- 23 percentage injected dose per gram).
257 -TOC (5.2 +/- 0.2 vs. 3.6 +/- 0.4 percentage injected dose per gram).
258  skin concentration of liposomes (percent of injected dose per gram).
259 minent tumor uptake (27.7 +/- 7.6 percentage injected dose per gram).
260 ografts expressing Y537S-ER (mean percentage injected dose per gram, 1.45 +/- 0.06; P = 0.77) and Y53
261 c-Met-negative MDA-MB-231 tumors (percentage injected dose per gram, 1.8 +/- 0.6 at 9 h after injecti
262 09 vs. 0.36 +/- 0.03, P < 0.0005; percentage injected dose per gram, 24 h: 3.24 +/- 0.65 vs. 1.63 +/-
263 F in c-Met-positive U87MG tumors (percentage injected dose per gram, 6.8 +/- 1.8 at 9 h after injecti
264  The tumor uptake was 1.1 +/- 0.3 percentage injected dose per gram, and the tumor-to-blood ratio was
265 entration in primary colon tumors was 0.016% injected dose per gram, compared with 0.004% in normal c
266 s as compared with the vena cava (percentage injected dose per gram, ctl: 21.4+/-6.1 vs. 10.0+/-3.9 v
267  (2.41 +/- 0.29 vs. 0.82 +/- 0.11 percentage injected dose per gram, P < 0.0001) was observed in L298
268 2A (16.9 +/- 2.2 vs. 13.4 +/- 1.7 percentage injected dose per gram, P = 0.07).
269 od (2.54 +/- 0.2 and 3.04 +/- 0.3 percentage injected dose per gram, respectively) indicating that (1
270  19.6 +/- 4.50, and 14.4 +/- 1.63 percentage injected dose per gram, respectively.
271 s 2.15 +/- 0.55 and 1.24 +/- 0.26 percentage injected dose per gram, respectively.
272 tumors 4 h after injection was 10 percentage injected dose per gram, which was 2-fold higher than in
273 d was measured to be 13.7 +/- 1.8 percentage injected dose per gram.
274 (18)F-FDG uptake was expressed as percentage injected dose per gram.
275 on PET/CT images and expressed as percentage injected dose per gram.
276 , 5.35 +/- 0.22 and 5.30 +/- 0.20 percentage injected dose per gram; n = 3 and 4).
277 nd 60 min after tracer injection [percentage injected dose per gram]: 1.8 +/- 0.7, 1.2 +/- 0.1, and 0
278 ; and H1975, 12.1 +/- 3.5 maximal percentage injected dose per milliliter).
279 CLI measurements were radiance, radiance per injected dose (radiance/ID), and total radiant volume.
280   Mean urinary excretion was 4.83 percentage injected dose (range, 0.64-12.41 percentage injected dos
281  no significant difference in the percentage injected dose recovered in the urine at 30 min and at 3
282 aging (2.2 +/- 0.4 vs. 1.4 +/- 0.3 cpm/mm(2)/injected dose, respectively, P < 0.05).
283  dose), and one third (very low dose) of the injected dose, respectively.
284 absolute gadolinium levels and percentage of injected dose, respectively.
285      All four imaging metrics (percentage of injected dose, SLN extraction, SLN uptake rate constant,
286 eted from the body at a higher percentage of injected dose than the nanorods at both the 7 and 28 day
287                           As a percentage of injected dose, the levels of gadolinium measured were co
288 1 pmol, which represented 16.5%-64.1% of the injected dose; the amount of dye within the SLNs ranged
289 portunity to deliver a large fraction of the injected dose to insonified tumors and produce a complet
290 any other tracer we examined (61.8% +/- 9.6% injected dose vs. 29.4% +/- 9.5% for (64)Cu-ATSM, P < 0.
291 osttransplant days 7 and 42, and the percent injected dose was computed for each graft.
292 a particle uptake indicated that >80% of the injected dose was in TAMs.
293 cumulate in tumours, whereas over 12% of the injected dose was recovered from the tumours of mice tre
294 d with any surfactants and a majority of the injected dose was taken up by the liver (>40%), while a
295  fluorescence in the blood pool (~40% of the injected dose) was similar for liposomes conjugated with
296                  Besides random noise in the injected dose, we found variation in peak parasite load
297 re were no system failures, and the error in injected doses when using automated injection was lower
298 afts was also observed using a 10-fold-lower injected dose with the tissue biodistribution assay.
299 n of all 3 tracers falling to less than 0.7% injected dose within 6 min.
300 (99m)Tc-HYNIC annexin V uptake as percentage injected dose (x10(-4)) decreased between days 1 and 7 b

 
Page Top